Literature DB >> 23204959

Percutaneous fasciotomy for the treatment of Dupuytren's disease-a systematic review.

Saoussen Salhi1, Etienne Cardin-Langlois, Mario Luc.   

Abstract

BACKGROUND: Dupuytren's disease is described as a thickening of the palmar fascia. It typically affects men of Northern European descent in their fifties. The disease process starts as a nodule at the distal palmar crease that progressively gives rise to a cord invading distally toward the finger. Historically, different treatments have been described. Our purpose was to perform a meta-analysis of the evidence published on the percutaneous fasciotomy (PCF) treatment.
METHODS: We searched Medline, PubMed, and the Cochrane Library for articles evalu ating the use of PCF for Dupuytren's disease. No study was excluded based on quality.
RESULTS: The search yielded nine studies. Because of their different methodologies, a meta-analysis could not be performed. However, we were able to extract common qualitative conclusions. PCF is an effective treatment modality for patients in whom general anesthesia is contraindicated, with a good outcome especially at the metacarpophalangeal joint, a low recurrence rate in the short term, and few complications.
CONCLUSIONS: Similar conclusions were reached by all the articles under study. Nevertheless, there remains the need for a prospective study with a higher statistical power and standardized clinical evaluation and surgical methods in order to achieve more objective quantitative results. It would also be pertinent to compare the outcomes and complication rates of PCF with the new collagenase treatment.

Entities:  

Keywords:  Dupuytren’s disease; Palmar fasciotomy; Percutaneous fasciotomy; Percutaneous release

Year:  2011        PMID: 23204959      PMCID: PMC3213253          DOI: 10.1007/s11552-011-9355-3

Source DB:  PubMed          Journal:  Hand (N Y)        ISSN: 1558-9447


  9 in total

1.  Percutaneous needle fasciotomy in dupuytren disease.

Authors:  G Foucher; J Medina; K Malizos
Journal:  Tech Hand Up Extrem Surg       Date:  2001-09

Review 2.  Dupuytren's disease: history, diagnosis, and treatment.

Authors:  Robert B Shaw; Alphonsus K S Chong; Andrew Zhang; Vincent R Hentz; James Chang
Journal:  Plast Reconstr Surg       Date:  2007-09       Impact factor: 4.730

3.  Needle fasciotomy for Dupuytren's disease: an Australian perspective.

Authors:  Matthew V K Lee; David Hunter-Smith
Journal:  ANZ J Surg       Date:  2009-11       Impact factor: 1.872

4.  The long-term results of closed palmar fasciotomy in the management of Dupuytren's contracture.

Authors:  A S Bryan; M S Ghorbal
Journal:  J Hand Surg Br       Date:  1988-08

5.  Percutaneous needle fasciotomy in dupuytren's disease.

Authors:  A L van Rijssen; P M N Werker
Journal:  J Hand Surg Br       Date:  2006-06-12

6.  Needle aponeurotomy for Dupuytren's contracture.

Authors:  H S Cheng; L K Hung; W L Tse; P C Ho
Journal:  J Orthop Surg (Hong Kong)       Date:  2008-04       Impact factor: 1.118

7.  Dupuytren's contracture--the role of fasciotomy.

Authors:  J Colville
Journal:  Hand       Date:  1983-06

8.  Assessment of percutaneous fasciotomy in the management of Dupuytren's contracture.

Authors:  D I Rowley; M Couch; R B Chesney; S H Norris
Journal:  J Hand Surg Br       Date:  1984-06

9.  Percutaneous needle aponeurotomy: complications and results.

Authors:  G Foucher; J Medina; R Navarro
Journal:  J Hand Surg Br       Date:  2003-10
  9 in total
  3 in total

Review 1.  Collagenase Treatment in Dupuytren Contractures: A Review of the Current State Versus Future Needs.

Authors:  Ilse Degreef
Journal:  Rheumatol Ther       Date:  2016-02-03

2.  [Percutaneous needle aponeurotomy for Dupuytren's disease].

Authors:  C K Spies; L P Müller; E Skouras; D Bassemir; P Hahn; F Unglaub
Journal:  Oper Orthop Traumatol       Date:  2015-08-25       Impact factor: 1.154

3.  Isolated and spontaneous correction of proximal interphalangeal joint contractures in Dupuytren's disease: an exploratory analysis of the efficacy and safety of collagenase Clostridium histolyticum.

Authors:  Michael J Hayton; Ardeshir Bayat; Douglass S Chapman; Robert A Gerber; Piotr P Szczypa
Journal:  Clin Drug Investig       Date:  2013-12       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.